No way [Dissolution / BCS / IVIVC]

posted by Ohlbe – France, 2019-01-27 19:18 (2205 d 05:53 ago) – Posting: # 19813
Views: 3,192

Dear yuvaneshwari,

❝ Since API is in solution state filled in capsule, its solubility/bioavailability is improved tremendously.


❝ In the above scenario, can we consider for BCS based waiver approach ?


I think you have answered your own question. If solubility is the limiting factor, and your product has an improved solubility compared to the reference, how could you justify any kind of biowaiver ?

In any case: BCS-based biowaivers are only possible for class I and III products. Not the slightest chance if you're dealing with class II or IV.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
23,376 posts in 4,912 threads, 1,662 registered users;
290 visitors (0 registered, 290 guests [including 20 identified bots]).
Forum time: 01:11 CET (Europe/Vienna)

Science is what you know.
Philosophy is what you don’t know.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5